TARP as antigen in cancer immunotherapy

Vanhooren, Jolien; Derpoorter, Charlotte; Depreter, Barbara; Deneweth, Larissa; Philippé, Jan; Moerloose, Barbara De; Lammens, Tim

doi:10.1007/s00262-021-02972-x

Cited by 3 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, incorrectly paired transferred TCRs may compete with one another for CD3, lowering the level of surface expression. There are a number of methods to prevent mispairing, such as murinizing human TCRs to give them a comparative benefit for the interaction of CD3 [151][152][153][154][155] .…”

Section: The Possibility Of Incorrect Matching Between the Exogenous ...mentioning

confidence: 99%

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Bibi,

Sarkar

2024

J Transl Genet Genom

View full text Add to dashboard Cite

Prostate cancer stands as the most prevalent cancer globally, constituting 21% of all cancer diagnoses in male patients. Urgent optimization of prostate cancer care is essential, given that this disease claims 345,000 lives every year. These innovative approaches hold substantial promise for both researchers and patients, representing a beacon of hope in the inhibitory act against prostate cancer. Prostate cancer's gradual advancement deems it suitable for immune therapy, but trials in metastatic cases show limited effectiveness, likely due to compromised immunity. Hindered by defective cellular responses, an immune-suppressive microenvironment, emerging evidence and breakthroughs, such as CAR-T therapy, inspire cautious optimism for advanced prostate cancer immunotherapy. Tumors utilize tactics to escape immune recognition, promoting the proliferation of MDSCs, Treg cells, and TAMs. Immunotherapy targets prostate cancer by mostly expressed target proteins and overexpressed target proteins. Immune cells play a role in tumor development and metastasis in advanced prostate cancer. Modulating the tumor microenvironment presents therapeutic possibilities. Certain prostate cancer types exhibit potential responses to immune checkpoint inhibitors, yet obstacles remain, necessitating additional research for enhanced efficacy. Immunotherapy faces hurdles in prostate cancer—limited inflammation, scarce antigens, and a resistant microenvironment. Grasping resistance intricacies is pivotal. The identification of DNA's helical structure propelled global progress in disease treatment through gene therapy. Choosing gene therapy vectors is critical; viruses are potent but toxic, while nonviral options, though less toxic, encounter barriers affecting transfection. In the realm of prostate cancer treatment, immunotherapy and gene therapy are emerging as increasingly viable options.

show abstract

Section: The Possibility Of Incorrect Matching Between the Exogenous ...mentioning

confidence: 99%

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Bibi,

Sarkar

2024

J Transl Genet Genom

View full text Add to dashboard Cite

show abstract

“…Specifically, arteries with mild neointima (+/-) contained heat shock proteins (CRYAB/HSBP5 and HSPB7) which increase in response to inflammatory stress 25,33 . Vessels with minimal neointima (1+) increased the antigen T-cell receptor (TARP) which promotes tumor cell proliferation and migration 34 . Vessels with moderate neointima (2+) increased a set of genes described in remodeling and EMT (TAGLN, CSRP1, and FLNA) 22,27,28 .…”

Section: Cav Lesion Progression Is Associated With Distinct Gene Expr...mentioning

confidence: 99%

Spatial Multi-omics of Arterial Regions from Cardiac Allograft Vasculopathy Rejected Grafts

Nevarez‐Mejia

Pickering

Sosa

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Cardiac allograft vasculopathy (CAV) is a major cause of late-graft failure and mortality following heart transplantation. The mechanisms underlying vascular remodeling are poorly understood. A major immune risk factor associated with the development of CAV is the presence of donor-specific antibodies (DSA) that induce chronic endothelial cell (EC) injury, leukocyte recruitment and inflammation resulting in thickening of arterial intima. Here, we molecularly characterized innate and adaptive immune cells present in the arteries of rejected cardiac allografts with DSA and identified protein and transcriptomic signatures distinguishing early and late CAV lesions. Methods: Arterial areas of interest (AOIs) from CAV+DSA+ rejected cardiac allografts (N=3; 2 females, 1 male) were subjected to GeoMx digital spatial profiling (DSP). AOIs were scored on the level of CAV progression/neointimal thickening (22 AOIs total; 11 high and 11 low neointima) and were subjected to whole transcriptome and protein profiling. Results: AOIs with low neointima significantly increased markers for activated inflammatory infiltrates, transcripts of EC activation and gene modules involved in activating metalloproteinases and TP53 regulation of caspases. Inflammatory and apoptotic protein markers significantly correlated with inflammatory modules in AOIs with low neointima. AOIs with high neointima increased TGF?-regulated transcripts and modules enriched for platelet activation/aggregation. Proteins encoding SMCs and growth factors/survival correlated with modules enriched for proliferation/repair in AOIs with high neointima. Key transcripts in promoting proliferation, migration, and EndoMT were significantly associated with increasing neointima scores. Conclusion: Our results reveal new protein and transcriptomic signatures associated with CAV progression. Lesions exhibiting inflammatory profiles appear to be early lesions that transition to later proliferative/pro-fibrotic phenotype CAV lesions. These findings should form the foundation for the identification of improved biomarkers to guide CAV treatment.

show abstract

“…Interestingly, TARP promotes tumor cell proliferation and migration, reflected in the poor survival rates [71,72]. Expression of TARP in malignant cells and its role in tumorigenesis while having limited expression in normal tissues have aroused interest regarding its potential use as a therapeutic target, which has led to the development of immunotherapy target strategies [73].…”

Section: Antigenmentioning

confidence: 99%

Recent advances in field effect transistor biosensor technology for cancer detection: a mini review

Chao

et al. 2021

J. Phys. D: Appl. Phys.

View full text Add to dashboard Cite

Cancer is an incurable disease, and the treatment process is extremely painful. Early detection may ease the treatment process and prevent cancer from spreading beyond the primary disease area. However, conventional screening tests have long detection times and lack the required sensitivity for early detection. Consequently, traditional cancer biosensors, including ARMS, digital PCR, next generation sequencing (NGS), western blot, electrochemical, and mechanical biosensors, have been studied in recent years. Specifically, field effect transistor (FET) biosensors, are attractive pocketable devices with short detection time capabilities. Because FET biosensors have outstanding electrical and mechanical properties, FET biosensors have been studied for their efficacy in the early detection of cancer. Traditional detection methods of cancer biomarkers include the use of FET biosensors for the detection of cancer biomarkers, especially gene, antigen, and protein characteristics. This review presents the latest strategies in FET applications in cancer biosensing and compares their advantages and disadvantages regarding sensing principle, configuration, and performance. Especially, FET biosensors for the detection of cancer biomarkers, which include antibodies, nucleic acids, proteins are highlighted. Mechanical and electrical properties of FET devices and their effect on performance is discussed. This review provides a guiding role in the design and development of FET-based biosensors.

show abstract

TARP as antigen in cancer immunotherapy

Cited by 3 publications

References 56 publications

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

New approaches and prospects of immunotherapy and gene therapy for prostate cancer

Spatial Multi-omics of Arterial Regions from Cardiac Allograft Vasculopathy Rejected Grafts

Recent advances in field effect transistor biosensor technology for cancer detection: a mini review

Contact Info

Product

Resources

About